# Vaccination With Flt3L, Radiation, and Poly-ICLC

> **NCT03789097** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 56 (estimated)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Metastatic Breast Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Flt3L
- **RADIATION:** Radiation
- **DRUG:** Poly ICLC

## Key facts

- **NCT ID:** NCT03789097
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-05
- **Primary completion:** 2025-03
- **Final completion:** 2025-03
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2024-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03789097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03789097, "Vaccination With Flt3L, Radiation, and Poly-ICLC". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03789097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*